Naianerios (Talk | contribs) (→Engagement) |
Naianerios (Talk | contribs) (→Engagement) |
||
Line 7: | Line 7: | ||
We tried to gather all of the opinions on the societal issues of CRISPR/Cas9 [[Team:Paris_Saclay/HP/Silver|the societal issues of CRISPR/Cas9]] from different fields, but also from public and professionals. We then tried to spread these informations amongst general audiences. | We tried to gather all of the opinions on the societal issues of CRISPR/Cas9 [[Team:Paris_Saclay/HP/Silver|the societal issues of CRISPR/Cas9]] from different fields, but also from public and professionals. We then tried to spread these informations amongst general audiences. | ||
− | Our concern about Public Engagement | + | Our concern about Public Engagement was so strong we made "[[Team:Paris_Saclay/HP/Gold#Inclusiveness_and_Deliberation|Inclusiveness]]" one of the principles of our Responsible Research and Innovation Test. To learn more about it, see our researches on [[Team:Paris_Saclay/HP/Gold|Responsible Research and Innovation]]. When we asked to 18 teams to fill this test we saw how much inclusiveness is important among iGEM teams. |
− | + | First, we tried to build a strong outreach. In order to do so, we did a [[Team:Paris_Saclay/HP/Silver#Synthetic_Biology_Survey|survey]] to know how much people knew about synthetic biology and the CRISPR/Cas9 technology and what were their feelings about it. We also made a vox pop [[Team:Paris_Saclay/HP/Silver#Vox_Pop|vox pop]] for the same reasons. Thus we explained more what these techniques represent through many exhibitions like the one at the Festival Vivant and the Nanterre University. | |
We also learned a lot on the CRISPR/Cas9 technology by meeting politics, scientists or patent attorneys [[Team:Paris_Saclay/HP/Silver#Meeting_Stakeholders|meeting politics, scientists or patent Attorneys]]. We conducted many interviews with people working with or about the CRISPR/Cas9 technology. We learned and the CRISPR/Cas9 technology but we also saw the great oppositions between people on science in general or the CRISPR/Cas9 technology in particular. | We also learned a lot on the CRISPR/Cas9 technology by meeting politics, scientists or patent attorneys [[Team:Paris_Saclay/HP/Silver#Meeting_Stakeholders|meeting politics, scientists or patent Attorneys]]. We conducted many interviews with people working with or about the CRISPR/Cas9 technology. We learned and the CRISPR/Cas9 technology but we also saw the great oppositions between people on science in general or the CRISPR/Cas9 technology in particular. | ||
At last, we connected public and stakeholders during a conference on the societal issues of the CRISPR/Cas9 technology.[[Team:Paris_Saclay/HP/Silver#Conference_about_The_Societal_Issues_of_CRISPR_Cas9|conference on the societal issues of CRISPR/Cas9]]. Our lecturer were Jean-Denis Faure, professor at AgroParisTech and Pierre Walrafen, patent Attorney. | At last, we connected public and stakeholders during a conference on the societal issues of the CRISPR/Cas9 technology.[[Team:Paris_Saclay/HP/Silver#Conference_about_The_Societal_Issues_of_CRISPR_Cas9|conference on the societal issues of CRISPR/Cas9]]. Our lecturer were Jean-Denis Faure, professor at AgroParisTech and Pierre Walrafen, patent Attorney. | ||
{{Team:Paris_Saclay/project_footer}} | {{Team:Paris_Saclay/project_footer}} |
Revision as of 15:37, 19 October 2016